When is JAK inhibitor treatment recommended for alopecia totalis?

Alopecia totalis is an autoimmune form of hair loss involving the scalp. JAK inhibitors act on immune signalling pathways that can contribute to inflammation around hair follicles. They do not suit everyone, and the choice depends on your medical history, current medicines, infection risk, pregnancy plans, and the pattern and activity of hair loss.

A consultation may include a scalp examination, review of how quickly hair was lost, and discussion of earlier treatments. Improvement, if it occurs, is assessed over time rather than assumed after the first doses. Hair can also change independently of treatment, so follow-up helps clarify the response.

Arrange a review with a dermatologist experienced in autoimmune hair loss. Bring a list of medicines and supplements, relevant medical conditions, vaccination details, and information about recent infections. Ask how the proposed medicine is taken, what monitoring is needed, and what alternatives exist if it is unsuitable.

Protect exposed scalp skin from sunlight and cold, and consider gentle head coverings if helpful. Avoid starting, stopping, or sharing a JAK inhibitor without medical guidance; the dose and follow-up plan are individual.

Contact your clinician promptly for fever, a persistent cough, painful skin changes, unusual weakness, or signs of an infection while taking treatment. Seek urgent help for trouble breathing, swelling of the face or throat, sudden chest pain, or one-sided weakness. These symptoms need assessment regardless of whether scalp hair is changing.

Ask whether your scalp examination supports alopecia totalis, what treatment goal is realistic, which health conditions or medicines affect safety, and how blood tests or other monitoring will be arranged. Clarify when to report infection symptoms and what plan will follow if treatment is paused.